-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Gan & Lee Pharmaceuticals. (SHSE:603087) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
Gan & Lee Pharmaceuticals. (SHSE:603087) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
Gan & Lee Pharmaceuticals. (SHSE:603087) shares have had a horrible month, losing 30% after a relatively good period beforehand. To make matters worse, the recent drop has wiped out a year's worth of gains with the share price now back where it started a year ago.
Although its price has dipped substantially, given close to half the companies operating in China's Biotechs industry have price-to-sales ratios (or "P/S") below 6.7x, you may still consider Gan & Lee Pharmaceuticals as a stock to potentially avoid with its 9.1x P/S ratio. However, the P/S might be high for a reason and it requires further investigation to determine if it's justified.
See our latest analysis for Gan & Lee Pharmaceuticals
What Does Gan & Lee Pharmaceuticals' Recent Performance Look Like?
With revenue growth that's inferior to most other companies of late, Gan & Lee Pharmaceuticals has been relatively sluggish. It might be that many expect the uninspiring revenue performance to recover significantly, which has kept the P/S ratio from collapsing. If not, then existing shareholders may be very nervous about the viability of the share price.
If you'd like to see what analysts are forecasting going forward, you should check out our free report on Gan & Lee Pharmaceuticals.What Are Revenue Growth Metrics Telling Us About The High P/S?
In order to justify its P/S ratio, Gan & Lee Pharmaceuticals would need to produce impressive growth in excess of the industry.
If we review the last year of revenue, the company posted a result that saw barely any deviation from a year ago. The lack of growth did nothing to help the company's aggregate three-year performance, which is an unsavory 26% drop in revenue. Therefore, it's fair to say the revenue growth recently has been undesirable for the company.
Turning to the outlook, the next year should generate growth of 31% as estimated by the two analysts watching the company. Meanwhile, the rest of the industry is forecast to expand by 825%, which is noticeably more attractive.
With this in consideration, we believe it doesn't make sense that Gan & Lee Pharmaceuticals' P/S is outpacing its industry peers. It seems most investors are hoping for a turnaround in the company's business prospects, but the analyst cohort is not so confident this will happen. There's a good chance these shareholders are setting themselves up for future disappointment if the P/S falls to levels more in line with the growth outlook.
What We Can Learn From Gan & Lee Pharmaceuticals' P/S?
There's still some elevation in Gan & Lee Pharmaceuticals' P/S, even if the same can't be said for its share price recently. Typically, we'd caution against reading too much into price-to-sales ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.
Despite analysts forecasting some poorer-than-industry revenue growth figures for Gan & Lee Pharmaceuticals, this doesn't appear to be impacting the P/S in the slightest. When we see a weak revenue outlook, we suspect the share price faces a much greater risk of declining, bringing back down the P/S figures. At these price levels, investors should remain cautious, particularly if things don't improve.
Plus, you should also learn about these 3 warning signs we've spotted with Gan & Lee Pharmaceuticals (including 2 which are significant).
Of course, profitable companies with a history of great earnings growth are generally safer bets. So you may wish to see this free collection of other companies that have reasonable P/E ratios and have grown earnings strongly.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Gan & Lee 制药。(SHSE: 603087)股价经历了一个糟糕的月份,在经历了相对不错的时期之后,股价下跌了30%。更糟糕的是,最近的下跌使一年的涨幅化为乌有,股价现在又回到了一年前的起点。
尽管其价格已大幅下跌,但鉴于近一半在中国生物技术行业运营的公司的市销率(或 “市销率”)低于6.7倍,您仍然可以将Gan & Lee Pharmicals视为可能避开的股票,其市销率为9.1倍。但是,市销率之高可能是有原因的,需要进一步调查以确定其是否合理。
查看我们对 Gan & Lee Pharmicals 的最新分析
Gan & Lee Pharmaceuticals的近期表现如何?
由于最近的收入增长不及大多数其他公司,Gan & Lee Pharmicals一直相对疲软。许多人可能预计,平淡无奇的收入表现将大幅恢复,这阻止了市销率的暴跌。如果不是,那么现有股东可能会对股价的可行性感到非常担忧。
如果你想了解分析师对未来的预测,你应该查看我们关于Gan & Lee Pharmicals的免费报告。关于高市盈率,收入增长指标告诉我们什么?
为了证明其市销率是合理的,Gan & Lee Pharmicals需要实现超过该行业的惊人增长。
如果我们回顾一下去年的收入,该公司公布的业绩与去年同期几乎没有任何差异。增长乏力无助于该公司的三年总体业绩,收入下降了26%,令人不快。因此,可以公平地说,最近的收入增长对公司来说是不可取的。
谈到前景,根据关注该公司的两位分析师的估计,明年将实现31%的增长。同时,该行业的其他部门预计将增长825%,这明显更具吸引力。
考虑到这一点,我们认为甘李制药的市盈率超过行业同行是没有道理的。看来大多数投资者都希望公司的业务前景出现转机,但分析师群体对这种情况的发生并不那么有信心。如果市盈率降至更符合增长前景的水平,这些股东很有可能为未来的失望做好准备。
我们可以从Gan & Lee制药的市销率中学到什么?
Gan & Lee Pharmaceuticals的市销率仍有所提高,尽管其最近的股价不能这样说。通常,在做出投资决策时,我们谨慎行事,不要过多地考虑市售比率,尽管这可以揭示其他市场参与者对公司的看法。
尽管分析师预测Gan & Lee Pharmicals的收入增长数据将低于行业,但这似乎丝毫没有影响市销率。当我们看到疲软的收入前景时,我们怀疑股价面临更大的下跌风险,从而使市销售率回落。在这些价格水平下,投资者应保持谨慎,尤其是在情况没有改善的情况下。
此外,您还应该了解我们在Gan & Lee Pharmicals发现的这3个警告信号(包括2个重要的警告信号)。
当然,具有良好收益增长历史的盈利公司通常是更安全的选择。因此,您可能希望看到这些免费收集的市盈率合理且收益增长强劲的其他公司。
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧